Association of adverse respiratory events with sodium-glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors among patients with type 2 diabetes in South Korea: a nationwide cohort study

被引：0
|
作者：
Han Eol Jeong
Sohee Park
Yunha Noh
Sungho Bea
Kristian B. Filion
Oriana H. Y. Yu
Seung Hun Jang
Young Min Cho
Dong Keon Yon
Ju-Young Shin
机构：
[1] Sungkyunkwan University,School of Pharmacy
[2] Sungkyunkwan University,Department of Biohealth Regulatory Science
[3] Biostatistics,Departments of Medicine and of Epidemiology
[4] and Occupational Health,Centre for Clinical Epidemiology
[5] McGill University,Division of Endocrinology and Metabolism
[6] Lady Davis Institute,Division of Pulmonary, Allergy, and Critical Care Medicine, College of Medicine
[7] Jewish General Hospital,Department of Internal Medicine
[8] Jewish General Hospital,Department of Translational Medicine
[9] McGill University,Department of Internal Medicine
[10] Hallym University Sacred Heart Hospital,Institute On Aging
[11] Hallym University,Department of Pediatrics
[12] Seoul National University College of Medicine,Department of Clinical Research Design & Evaluation, Samsung Advanced Institute for Health Sciences & Technology (SAIHST)
[13] Seoul National University College of Medicine,undefined
[14] Seoul National University Hospital,undefined
[15] Seoul National University,undefined
[16] Medical Science Research Institute,undefined
[17] Kyung Hee University College of Medicine,undefined
[18] Kyung Hee University Medical Center,undefined
[19] Kyung Hee University College of Medicine,undefined
[20] Sungkyunkwan University,undefined
来源：
BMC Medicine | / 21卷
关键词：
Sodium-glucose cotransporter 2 inhibitors; Respiratory effectiveness; Type 2 diabetes; Population-based cohort;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors
    Ann Wan-Chin Ling
    Cze-Ci Chan
    Shao-Wei Chen
    Yi-Wei Kao
    Chien-Ying Huang
    Yi-Hsin Chan
    Pao-Hsien Chu
    Cardiovascular Diabetology, 19
  • [42] Risk of dementia after initiation of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in adults aged 40-69 years with type 2 diabetes: population based cohort study
    Shin, Anna
    Koo, Bo Kyung
    Lee, Jun Young
    Kang, Eun Ha
    BMJ-BRITISH MEDICAL JOURNAL, 2024, 386
  • [43] Comparison between sodium-glucose cotransporter 2 inhibitors and dipeptidyl peptidase 4 inhibitors on the risk of incident cancer in patients with diabetes mellitus: A real-world evidence study
    Sung, Hui-Lin
    Hung, Chuan-Yu
    Tung, Yu-Chun
    Lin, Chih-Chung
    Tsai, Tung-Han
    Huang, Kuang-Hua
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2024, 40 (03)
  • [44] Adverse cardiovascular and limb events in diabetic patients after peripheral artery disease revascularization treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors
    See, Lai-chu
    Lee, Hsin-Fu
    Li, Pei-Ru
    BRITISH JOURNAL OF PHARMACOLOGY, 2023, 180 : 260 - 262
  • [45] Combined effect of sodium-glucose cotransporter 2 and dipeptidyl peptidase-4 inhibitors for diabetic kidney disease
    Araki, Shin-ichi
    JOURNAL OF DIABETES INVESTIGATION, 2020, 11 (01) : 22 - 24
  • [46] Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study
    Ueda, Peter
    Svanstrom, Henrik
    Melbye, Mads
    Eliasson, Bjorn
    Svensson, Ann-Marie
    Franzen, Stefan
    Gudbjornsdottir, Soffia
    Hveem, Kristian
    Jonasson, Christian
    Pasternak, Bjorn
    BMJ-BRITISH MEDICAL JOURNAL, 2018, 363
  • [47] Risk of morbidity and mortality in patients with type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitor and/or dipeptidyl peptidase-4 inhibitor: a nationwide study
    Suto, Gabor
    Molnar, Gergo A.
    Rokszin, Gyorgy
    Fabian, Ibolya
    Kiss, Zoltan
    Szekanecz, Zoltan
    Poor, Gyula
    Jermendy, Gyorgy
    Kempler, Peter
    Wittmann, Istvan
    BMJ OPEN DIABETES RESEARCH & CARE, 2021, 9 (01)
  • [48] Risk of hospitalization with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes lacking evidence of chronic kidney disease: Real-world data
    Schechter, Meir
    Cohen, Cheli Melzer
    Zelter, Tamir
    Yanuv, Ilan
    Rozenberg, Aliza
    Chodick, Gabriel
    Karasik, Avraham
    Mosenzon, Ofri
    DIABETES OBESITY & METABOLISM, 2023, 25 (10): : 3054 - 3058
  • [49] Favorable pleiotropic effects of sodium glucose cotransporter 2 inhibitors: head-to-head comparisons with dipeptidyl peptidase-4 inhibitors in type 2 diabetes patients
    Shih-Chieh Shao
    Kai-Cheng Chang
    Swu-Jane Lin
    Rong-Nan Chien
    Ming-Jui Hung
    Yuk-Ying Chan
    Yea-Huei Kao Yang
    Edward Chia-Cheng Lai
    Cardiovascular Diabetology, 19
  • [50] Favorable pleiotropic effects of sodium glucose cotransporter 2 inhibitors: head-to-head comparisons with dipeptidyl peptidase-4 inhibitors in type 2 diabetes patients
    Shao, Shih-Chieh
    Chang, Kai-Cheng
    Lin, Swu-Jane
    Chien, Rong-Nan
    Hung, Ming-Jui
    Chan, Yuk-Ying
    Yang, Yea-Huei Kao
    Lai, Edward Chia-Cheng
    CARDIOVASCULAR DIABETOLOGY, 2020, 19 (01)
12345